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PRE-EMPT
StillbirthWhilewe believe that pre-eclampsiamatters—because it remains a leading cause ofmaternal and perinatalmor-
bidity andmortality worldwide—we are convinced that the time has come to look beyond single clinical entities
(e.g. pre-eclampsia, postpartum hemorrhage, obstetric sepsis) and to look for an integrated approach that will
provide evidence-based personalized care to women wherever they encounter the health system. Accurate out-
come prediction models are a powerful way to identify individuals at incrementally increased (and decreased)
risks associated with a given condition. Integrating models with decision algorithms into mobile health
(mHealth) applications could support community and ﬁrst level facility healthcare providers to identify those
women, fetuses, and newborns most at need of facility-based care, and to initiate lifesaving interventions in
their communities prior to transportation. In our opinion, this offers the greatest opportunity to provide distrib-
uted individualized care at scale, and soon.
© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology andObstetrics. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and
Treatment), a Bill & Melinda Gates Foundation-funded initiative, is
designed to develop, test, and introduce new knowledge to reduce the
unacceptable maternal, perinatal, family, societal, and global impacts of
pre-eclampsia, and the other hypertensive disorders of pregnancy [1,2].
At the time of publication,wewill be ﬁve of seven years into the initiative.
We believe that pre-eclampsia matters because it remains a lead-
ing cause of maternal and perinatal morbidity and mortality world-
wide [3,4]. However, in parallel with our current focus on pregnancyvenue, Vancouver, BCV5Z 4H4,
behalf of International Federation ofhypertension, we are convinced that the time has come to look beyond
single clinical entities (e.g. pre-eclampsia, postpartum hemorrhage
[PPH], obstetric sepsis) to look for an integrated approach that will pro-
vide evidence-based personalized care to women wherever they en-
counter the health system. In our view, only an integrated approach
(across disease entities and between community and facility) will over-
come all three delays in triage, transport, and treatment that make indi-
vidual women vulnerable to maternal mortality [5].2. Outcome prediction: The key to distributed personalized medicine
In our opinion, major advances in maternal, fetal, and newborn
health can be achieved through making outcome prediction models
available to women, parents, their families, and all levels of healthcareGynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
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absolute numbers, the ongoing British Conﬁdential Enquiries into Ma-
ternal Deaths provide evidence that the introduction of the National
Health Service with free maternity care and, soon thereafter, reproduc-
tive choice was associated with a rapid decline in the number of mater-
nal deaths attributed to the hypertensive disorders of pregnancy,
primarily pre-eclampsia and eclampsia (Fig. 1). The accelerating pattern
of maternity care (four-weekly visits until 28 weeks, fortnightly to
36 weeks, and weekly thereafter) was designed in Edinburgh largely
for the identiﬁcation of pre-eclampsia to afford the opportunity
for timely delivery [6]. Since the ﬁrst triennial report (1952–54), pre-
eclampsia- and eclampsia-related deaths have fallen by approximately
90%. Over 90% of that fall was achieved prior to the introduction of
either effective antihypertensives for the management of pregnancy
hypertension [7] or the use in the UK of magnesium sulfate (MgSO4)
for eclampsia prevention and treatment following the Collaborative
Eclampsia and Magpie Trials, respectively [8,9]. Similar data exist for
Sri Lanka following the introduction of comprehensive maternity care,
including vital registration, registration of midwives, prenatal coverage
(health center- and home-based), and facility strengthening [10].
Therefore, the process of individualized risk assessment through prena-
tal care is an effective tool for reducing adverse pregnancy outcomes, es-
pecially when included in a package of health service enhancements.
Accurate outcome prediction models are a powerful way to identify
individuals at incrementally increased (and decreased) risks associated
with a given condition [11]. By stratifying the population into true risk
groups, interventions and timely delivery can be targeted to those most
in need so that maximum beneﬁt is achieved in a resource-constrained
setting. For mothers, fetuses, and newborns, examples of such conditions
could be pre-eclampsia, decreased fetalmovements, or sepsis, respective-
ly. Approximately half of maternal deaths occur in the home [12], so it is
critical to develop a distributed model of diagnosis and risk assessment.
To do so, there are two challenges that need to be addressed:
(1) To be able to identify, fromwithin a population with such condi-
tions, the speciﬁc individuals who are likely to become critically
unwell prior to their clinical decompensation (e.g. development
of seizures or sepsis) so that they can receive early interventions
(e.g.MgSO4 or antibiotics) and, if they are still in the community,
so that they can be transported rapidly for deﬁnitive, facility-
based care. For use in resource-constrained settings at the com-
munity level, such outcome prediction models can include only
demographics, symptoms, and signs (augmented by low-cost,
noninvasive, robust but accurate sensors to measure bloodJo
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Fig. 1.Modiﬁed fromWhymothers die 2000–2002. Report on conﬁdential enquiries into mater
probable rate of decline without the introduction of the National Health Service (NHS). Vert
maternity outcomes.pressure, temperature, or pulse oximetry) while ﬁndings from
laboratory tests could also be added as predictors for use at the
facility level.
(2) To develop clinical algorithms that respond to levels of risk using
predictive modelling techniques that incorporate guidance from
theWHO, other organizations that promulgate expert guidelines,
and large robust clinical data sets, tailored to the various settings
(i.e. community vs primary health center vs inpatient facility in
resource-constrained vs well-resourced settings).
Within the scope of our activities, we have developed and validated
two outcome prediction models, the PIERS (Pre-eclampsia Integrated
Estimate of RiSk) models that identify those pregnant women with
pre-eclampsia who are most likely to develop life-threatening compli-
cations. Both models have accurate ability to identify women at low
risk of developing imminent complications.
The fullPIERS model, which includes demographics, symptoms [13],
pulse oximetry [14], and maternal laboratory tests [15,16], identiﬁes
clinical relevant risk categories (area under the curve of the receiver−
operator characteristic [AUC ROC] 0 · 88 [95% CI, 0 · 84 − 0 · 92])
[17,18]. Currently, fullPIERS is undergoing external validation; a prelim-
inary validation exercise is reassuring [19].
The validated miniPIERS model is solely demographics-, symptom-,
and sign-based and can be administered by (1) community healthcare
providers (cHCPs ) in the home and at primary health centers; and
(2) facility-based practitioners as they initially triage women admitted
with pregnancy hypertension prior to the availability of laboratory re-
sults (or in lieu of laboratory results in some less-developed settings)
(AUC ROC 0.77 [95% CI, 0.74− 0.80]) [20].
The PIERS on the Move (POM) smart phone app integrates
miniPIERS and clinical decision algorithms to support cHCPs (e.g. Lady
Health Workers in Pakistan) as they provide prenatal care, diagnose
pre-eclampsia, and initiate lifesaving therapies in the woman’s home
prior to urgent transfer to an effective facility [21–23] (Fig. 2). When
using the miniPIERS model alone, and if we choose a 25% probability
for developing an adverse outcome as a threshold for “high risk,” we
identify 65% of women who will go on to suffer a severe complication.
Through the POMprojectwe have learnt that, by adding pulse oximetry,
using the same 25% risk threshold, we improve the prediction rate to
85% of women who will go on to suffer a severe complication [22].
Currently, the POM app is being tested at scale in the Community-
Level Interventions for Pre-eclampsia (CLIP) Trials in Nigeria,
Mozambique, Pakistan, and India with pulse oximetry limited toan
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ical lines represent important dates in the evolution of health care in the UK relevant to
Fig. 2. PIERS on the Move mHealth application screenshots (Nigerian version of pictograms).
S12 P. von Dadelszen et al. / International Journal of Gynecology and Obstetrics 131 (2015) S10–S15Mozambique and Pakistan (http://pre-empt.cfri.ca/treatment/clip-trial;
accessedNovember 10, 2014).Within the context of the CLIP Trial, hyper-
tensivewomen identiﬁedwithin their community to be at greatest risk of
maternal complications receive 10 g intramuscular MgSO4 and, with se-
vere hypertension, oral 750 mg methyldopa prior to urgent referral to a
referral facility (i.e. completed referral within four hours). In CLIP inter-
vention clusters, all women identiﬁed as being hypertensive are referred
to facilities within 24 hours as none is without risk and many will have
disease evolution to more severe disease.
3. Translational biomarkers at point of care
It is clear that the identiﬁcation of angiogenic imbalance, especially
decreased maternal serum placental growth factor (PlGF) concentra-
tions, strengthens the ability to identify women with pre-eclampsia
when clinical uncertainty exists [24,25]. From the PELICAN Study, it ap-
pears that PlGF has the additional beneﬁt of being able to discriminate
between women who are most unwell with pre-eclampsia from those
who are least unwell [24]. There is ongoing research to investigate
how PlGF might strengthen the PIERS models. However, the largestdiagnostic beneﬁt of PlGF appears to be prior to 35 + 0 weeks of preg-
nancy, whereas themajority of pre-eclampsia (and associatedmaternal
deaths) arises nearer to, or at, term. In addition, to bemost useful in less
developed settings, a low cost, whole blood point-of-care diagnostic
platform, as in HIV management, for example [26], is required. Finally,
low maternal serum PlGF is not speciﬁc to pre-eclampsia, but is ob-
served inwomenwith small-for-dates fetuses due to placental dysfunc-
tion (but not constitutionally small fetuses) [27].
Low PlGF appears to identify a pregnancy complicated by placental
dysfunction and/or failure. This last point may be important in terms
of the generalizability of PlGF to obstetric populations at scale.4. Looking beyond hypertension to hypotension: Labor and
the puerperium
We are conﬁdent that the PIERSmodel and POM app can guide indi-
vidualized care and improve outcomes for women with pregnancy
hypertension; however, pregnancy hypertension only accounts for ap-
proximately 15% of maternal deaths [4].
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tality are prolonged labor, PPH, and puerperal sepsis [4]. To us, a priority
is to develop (an) outcome prediction model(s) comparable to the
PIERS models so that women vulnerable to labor, postpartum, and
puerperal complications can be identiﬁed before they clinically
decompensate. We anticipate that all such models will include pulse
oximetry—the “ﬁfth vital sign” [28].
Women thus identiﬁed could have lifesaving therapy initiated in the
community or at ﬁrst level facility (e.g. antibiotics or a heat stable
uterotonic), and be referred urgently for evidence-based deﬁnitive
care at a higher level. Such an approach would have the added beneﬁt
of being able to detect deterioratingmaternal health due to intercurrent
communicable (e.g. HIV, malaria, tuberculosis) and noncommunicable
(e.g. acquired valvular heart disease), in addition to direct obstetric
causes of maternal death.
To this end, we have developed a modiﬁed blood pressure device
(Microlife 3AS1-2; Microlife, Widnau, Switzerland) speciﬁcally for use
in low- and middle-income countries (LMICs), which fulﬁls WHO re-
quirements for suitability for use in low-resource settings [29]. The de-
vice has been validated for use in both non-pregnant and pregnant
populations (including both women with pre-eclampsia and low
blood pressure), according to the British Hypertension Society protocol
[29,30]. It has been evaluated in a feasibility study in Sub-Saharan Africa
(Tanzania, Zambia, and Zimbabwe) and shown to be acceptable, feasi-
ble, and resulted in increased referrals to higher level institutions for
suspected hypertensive disorders by cHCPs.
We have determined the normal range of conventional vital signs as
well as shock index, which is the ratio of heart rate to systolic blood
pressure. Thereafter, we retrospectively analyzed datasets of women
with PPH (one dataset in the UK and another large dataset of women
in four African low-resource settings) to evaluate the predictive value
of conventional vital signs and shock index. The shock index was
shown to be a more consistent predictor of adverse clinical outcomes
than conventional vital signs. Currently, we are evaluating our retro-
spectively determined thresholds for the shock index, relating to in-
creased risk of adverse outcome. Based on these results, we expect
that the shock index will be used as a trigger for action to help guide
cHCPs and staff at ﬁrst level facilities.
A trafﬁc light earlywarning systemhas been incorporated into the de-
vice, to alert users to abnormalities in blood pressure and pulse, using
these developed shock index thresholds along with well-recognized
thresholds to indicate hypertension in pregnancy. For the shock index
(SI), a green light (SI threshold b0.9) would provide reassurance, an
amber light (SI ≥0.9 and ≤1.7) indicates need for intervention, and a red
light (SI ≥1.7) indicates the need for urgent referral to higher level facili-
ties. These thresholds are being validated prospectively.
5. Stillbirth and newborn health
While the focus of the present paper is maternal health, we believe
that the greatest advantage can be obtained through integration ofmater-
nal, fetal, and newborn health silos. In brief, stillbirth remains an under-
recognized and under-investigated scourge [31]. The daily toll of lost
wanted fetuses is unacceptable; however, we consider that it should be
possible to combine maternal awareness of fetal well-being (e.g. fetal
movements), mHealth-supported fetal heart screening and, quite proba-
bly, the point-of-care use of a biomarker such as PlGF to identify individ-
ual fetuses at increased risk of stillbirth prior to the occurrence of that
devastating complication. Such an outcome predictionmodel could be in-
tegrated into a maternal− fetal− newborn mHealth platform.
In addition, pulse oximetry has been shown to be an effective
screening tool for congenital heart disease and early newborn sepsis
[32,33]. Integration of pulse oximetry into a community-based newborn
outcome prediction model such as the TRIPS score might enable cHCPs
and staff at ﬁrst level facilities to deliver effective newborn screening,
risk identiﬁcation, and initiation of lifesaving therapies in the homeprior to transfer [34,35]. In time, this approach could be extended to
cover the leading causes of mortality in children under ﬁve years old:
diarrhea and pneumonia [36].
6. Long-term maternal health: Pregnancy as a risk identiﬁer for
noncommunicable diseases
In addition to the peripartum advantages offered to women by such
an integratedmHealth platform, there is an opportunity to intervene to
the beneﬁt of women’s long-term health. While there is increasing rec-
ognition of the role of pre-eclampsia as a risk identiﬁer for premature
cardiovascular disease [37], as is well recognized for gestational diabe-
tes and type 2 diabetes [38], what is less well recognized is the associa-
tion of a whole range of “placental complications” of pregnancy with
cardiovascular disease [39,40].
Using data from the Scottish health dataset, Smith et al. [39] identi-
ﬁed thatmaternal risk of ischemic heart disease admission or deathwas
associatedwith delivering a baby in the lowest birthweight quintile (i.e.
b20th percentile) for gestational age (adjusted hazard ratio [aHR] 1.9
[95% CI, 1.5− 2.4]), preterm delivery (b37 + 0 weeks; aHR 1.8 [95%
CI, 1.3− 2.5]), and pre-eclampsia (aHR 2.0 [95% CI, 1.5− 2.5]). These
associations were additive as women with all three characteristics had
a seven-fold greater risk of ischemic heart disease admission or death
(95% CI, 3.3− 14.5) than normotensive women delivering appropriate-
ly grown babies at term [39]. These data conform to other datasets,
linking pregnancy outcomes with noncommunicable diseases [37,40].
This may be very important in the context of less developed countries.
Inmost countries, health provision formothers is dissociated frompedi-
atric care after birth, although it is usually mothers who bring their chil-
dren for that care.
Given the ability to use pregnancy to identifywomenwith increased
cardiovascular and endocrine risks, there exists an opportunity to
use childhood immunization infrastructures to support targeted
ongoing surveillance of blood pressure, urine, and glucose for women
who have had complicated pregnancies. Such an approach would be fa-
cilitated by a maternal − newborn − child mHealth platform that
maintains the link between women and their children to coordinate
clinical care.
7. Community versus facility focus
Our experience with the PIERS models informs us that it is possible
to identify those who would most beneﬁt from focused and timely
facility-based care. There is a compelling argument that all pregnant
women should receive woman-friendly facility-based intrapartum
care, despitemany health systems remaining challenged to provide suf-
ﬁcient resources to offer such care to all pregnant and laboring women.
At present, there is a pressing need to determine whether or not
community-level risk stratiﬁcation can accurately identify and promote
access for those women who require urgent transfer to and manage-
ment and delivery in a facility under routine conditions. We are more
conﬁdent that facility-based risk stratiﬁcation will support personnel
to respond to individualized risks and to prioritize the care of those
women in greatest need.
Through an integrated mHealth-supported approach, which in-
cludes elements such as diagnostic and decision algorithms, prenatal
visit booking, and text reminders, we will be able to offer personal-
ized risk assessment to women in their homes or primary health
centers. This would provide an evidence-based, portable continuum
of care from home to hospital that can be used by all level of
healthcare workers. Our view is all levels, across this continuum
from home to hospital, need strengthening in parallel, achieving com-
plementarity between the community and facilities and prioritizing
facility resources to those women, fetuses, and newborns who will
most beneﬁt.
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Clearly, none of this will be effective without engaging communities
to gain buy-in, especially around the uptake of innovations [41–43].
Many societies hold a conservative and limiting viewofwomen’s auton-
omy and value within their family and community. Individuals such as
community leaders, faith leaders, traditional and political leaders,
volunteers, and traditional birth attendants should be engaged in the
process of implementing any mHealth-supported approach that intro-
duces new technologies and task shifting to community members.
9. Integration with existing health system strategies
Aswith communities, somust thosewhowish to innovate across the
maternal− fetal− newborn continuum engage with, and take into ac-
count, existing health system strategies and interventions [42–45]. In
our view, to be attractive to those who fund health delivery, whether
governments, multilaterals, nongovernmental organizations, or the pri-
vate sector, strategies for mHealth-supported individualized care must
be integrated into existing and evolving health systems, and be compre-
hensive enough to be attractive to implementers. Attempting to create a
parallel platformwill be counterproductive in the long term, as it will be
unsustainable by design. Engagement with decision makers and
thought leaders from the initial design phase of an interventionwill im-
prove ownership and the likelihood of implementation at scale. Again, it
is our opinion that trials and implementation projects ofmHealth-based
interventions require health economic analyses that clearly show to
those who make often difﬁcult decisions what the return will be on
the resources invested. As a benchmark for comparison, in 2001 US
dollars, it cost $12 942, $1179, and $263 to avoid one seizure of
eclampsia using MgSO4 in high-, middle- and low-income countries,
respectively, limiting its use to women with severe pre-eclampsia [46].
10. Summary
As a group of investigators coming from apparently disparate
academic foci in obstetrics, maternal medicine, midwifery, newborn
medicine, pediatric anesthesia, infectious diseases medicine, and elec-
trical and computer engineering, we are of a joint view that we can ac-
celerate progress toward Millennium Development Goals 4 and 5
through integrated efforts that take us out of our silos. In our opinion,
the use of scientiﬁcally robust outcome prediction models integrated
with decision and intervention algorithms into mHealth applications
offer the greatest opportunity to provide distributed individualized
care at scale, and, if resources can be found to undertake the remaining
work quickly, soon.
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